THE FIRST AND ONLY FDA-APPROVED
LIQUID STATIN THAT HELPS LOWER CHOLESTEROL

Sign up here to become a Direct Purchase Customer.

For existing customers, click here to place your order.

Over 15 million Americans use a statin to help lower cholesterol

69% of older patients report difficulty swallowing pills

FloLipid is available in 20mg/5mL & 40mg/5mL formulations

NO REFRIGERATION REQUIRED 

Smooth liquid/syrup consistency and texture with a pleasant strawberry flavor

  • Formulated for those who have difficulty swallowing pills

    ​Helps reduce the level of LDL cholesterol and triglycerides

    ​Helps to increase HDL cholesterol levels

    ​It helps lower the risk of stroke, heart attack, and other complications for patients at risk due to diabetes and coronary heart disease.

    ​FDA Approved 

    start today

  • 15 million Americans use a statin drug for their cholesterol

    69% of Older patients reported difficulty swallowing pills

    Only Statin medication is available in liquid form

    More Info

  • Bioequivalent to Zocor (simvastatin)

    Available in 20mg/5mL and 40mg/5mL

    May be easier for patients with swallowing issues 

    No refrigeration required

    Approved by FDA

    Pleasant strawberry flavor

    interested?

flolipid oral suspension

20mg/ 5mL

Strength: 20mg per 5mL

Quantity: 1 bottle (150mL)

Concentration 4mg per mL

Prescription Only

40mg/ 5ml

Strength: 40mg per 5mL

Quantity: 1 bottle (150mL)

Concentration 8mg per mL

Prescription Only

INDICATIONS

FloLipid™ Oral Suspension (simvastatin) is an HMG-CoA reductase inhibitor indicated as an adjunct to diet to:
- Reduce the risk of total mortality by reducing coronary heart disease (CHD) deaths and to reduce the risk of non-fatal myocardial infarction, stroke, and the need for coronary and non-coronary revascularization procedures in patients at high risk of coronary events
- Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG) and increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia
- Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and very-low-density lipoprotein cholesterol (VLDL-C) in patients with primary dysbetalipoproteinemia
- Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia
- Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy
- Limitations of Use: FloLipid Oral Suspension has not been studied in Fredrickson types I and V hyperlipidemia

IMPORTANT SAFETY INFORMATION

FloLipid Oral Suspension is contraindicated:
- With concomitant administration of strong CYP3A4 inhibitors, gemfibrozil, cyclosporine, or danazol
- In patients with a known hypersensitivity to any component of the medication
- In patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels
- In women who are or may become pregnant or who are nursing Increased risk of myopathy, including rhabdomyolysis, has been associated with the 80-mg dose of FloLipid Oral Suspension
- Risk increases with concomitant use of certain medicines
- Predisposing factors include advanced age (≥65), female gender, uncontrolled hypothyroidism, and renal impairment
- Patients should be advised to report promptly any unexplained and/or persistent muscle pain, tenderness, or weakness
- FloLipid Oral Suspension therapy should be discontinued immediately if myopathy is diagnosed or suspected
- Monitoring of creatine phosphokinase levels is merited in patients with a history of renal insufficiency

For more information, please see the full Prescribing Information and Patient Information for FloLipid Oral Suspension

Click above for product information